pH, Healing rate and symptom relief in acid-related diseases

Yale Journal of Biology and Medicine

Volumn 69, Issue 2, 1996, Pages 159-174

  Huang, Jia Qing ^a   Hunt, Richard H ^a  

^a MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; ANTIINFECTIVE AGENT; BILE ACID; BISMUTH SALICYLATE; CLARITHROMYCIN; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; METRONIDAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PEPSIN A; PLACEBO; PROTON PUMP INHIBITOR; RANITIDINE; STOMACH SECRETION INHIBITOR; TETRACYCLINE;

ARTICLE; CLINICAL TRIAL; DUODENUM ULCER; ESOPHAGITIS; GASTROESOPHAGEAL REFLUX; HELICOBACTER PYLORI; HUMAN; STOMACH ACID SECRETION; STOMACH PH; STOMACH ULCER; SYMPTOMATOLOGY; ULCER HEALING;

ANTI-ULCER AGENTS; BILE ACIDS AND SALTS; CLINICAL TRIALS; DUODENAL ULCER; GASTRIC ACID; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; HYDROGEN-ION CONCENTRATION; PAIN; PEPSIN A; PEPTIC ULCER; STOMACH ULCER;

HELICOBACTER PYLORI;

EID: 12644296004     PISSN: 00440086     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (123)

1. Marshall, B.J, and Warren, J.R. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet I:1311-1314, 1984
2. Tytgat, G. and Dixon, M.F. Overview. In: Northfield, T.C., Mendell, M., and Goggin, P.M., eds. Helicobacter pylori Infection: Pathology, Epidemiology and Management. London: Kluwer Academic Publishers; 1993, 75-87
3. El-Omar, E.M., Penman. I.D,. Ardill, J.E.S., Chillajallu, R.S., Howie, C., and McColl, K.E.L. Helicobacter pylori infection and abnormalities of acid secretion in patients with duodenal ulcer disease. Gastroenterology 109:681-691, 1995.
4. McColl, K.E.L., Fullarton, G.M., Chittajallu, R., Nujumi, A.M.E.L., MacDonald, A.M.I, Dahill, S.W., and Hillditch, T.E. Plasma gastrin, daytime intragastric pH, and nocturnal acid output before and one and seven months after eradication of Helicobacter pylori in duodenal ulcer subjects. Scand. J. Gastroenterol. 26:339-346, 1991.
5. Jacobson, K., Chiba, N., Barrientos, M., and Hunt, R.H. Short-term effect on acid secretory response and parietal cell sensitivity in H. pylori-positive DU patients following eradication. Gastroenterology 106:A100, 1994.
6. Mohamed, A.H., Wilkinson, J., and Hunt, R.H. Duodenal ulcer recurrence after Helicobacter pylori (Hp) eradication: a meta-analysis. Gastroenterology 106:A142, 1994.
7. Hunt, R.H. pH and Hp-gastric acid secretion and Helicobacter pylori: implications for ulcer healing and eradication of the organism. Am. J. Gastroenterol. 88:481-483, 1993.
8. Burget, D.W., Chiverton, S.G., and Hunt, R.H. Is there an optimal degree of acid suppression for healing of duodenal ulcers? A model of the relationship between ulcer healing and acid suppression. Gastroenterology 99:345-351, 1990.
9. Bell, N.I.V., Burget, D., Howden, C.W., Wilkinson, J., and Hunt, R.H. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion 51(suppl 1):59-67, 1992.
10. Howden, C.W., Burget, D.W., and Hunt, R.H. A meta-analysis to predict gastric ulcer healing from acid suppression. Gastroenterology 100:A3, 1991.
11. Goldberg, H.I., Dodds, W.J., Gee, S., Montgomery, C., and Zboralske, F.F. Role of acid and pepsin in acute experimental esophagitis. Gastroenterology 56:223-230, 1969.
12. Moore J.G. and Englert E. Circadian rhythm of gastric acid secretion in man. Nature 226:1261-1262, 1970.
13. Lanzon-Miller, S., Pounder, R.E., Hamilton, M.R., Chronos, N.A.F., Ball, S., Mercieca, J.E., Olausson, M., and Cederberg, C. Twenty-four-hour intragastric acidity and plasma gastrin concentration in healthy subjects and patients with duodenal or gastric ulcer, or pernicious anaemia. Aliment. Pharmacol. Therap. 1:225-237, 1987.
14. Shamburek, R.D. and Schubert, M.L. Structure and function of the stomach role of the proton pump. In Hunt, R.H., ed. Proton Pump Inhibitors and Acid-Related Diseases. Osaka: Adis International Ltd.; 1994.
15. Helander, H.F. and Keeling, D.J. Cell biology of gastric acid secretion. Baillieres Clin. Gastroenterol. 7:1-21, 1993.
16. Dent, J., Holloway, R.H., Toouli, J., and Dodds, W.J. Mechanism of lower esophageal sphincter incompetence in patients with symptomatic gastroesophageal reflux. Gut 29:1020-1028, 1988.
17. Helm, F. Esophageal acid clearance. J. Clin. Gastroenterol. 8(suppl 1):5-11, 1986.
18. Little, A.G., DeMeester, T.R., Rezai-Zadeh, K., and Skinner, D.B. Abnormal gastric emptying in patients with gastroesophageal reflux. Surg. Forum 28:347-348, 1977
19. Gotley, D.C., Morgan, A.P., and Cooper, M.J. Bile acid concentration in the refluxate of patients with reflux oesophagitis. Br. J. Surg. 75:587-590, 1988.
20. Hirschowitz, B.I. A critical analysis with appropriate controls of gastric acid and pepsin secretion in clinical esophagitis. Gastroenterology 101:1149-1158, 1991.
21. Joelsson, B. and Johnsson, F. Heartburn-the acid test. Gut 30:1523-5, 1989.
22. Smith, J.L., Opekun, A.R., Larkai, E., and Graham, D.Y. Sensitivity of the esophageal mucosa to pH in gastroesophageal reflux disease. Gastroenterology 96:683-689, 1989.
23. Gotley, D.C., Morgan, A.P., Ball, D., Owen, R.W., and Cooper, MJ. Composition of gastrooesophageal refluxate. Gut 32:1093-9, 1991.
24. Kiriluk, L.B. and Merendino, K.A. Comparative sensitivity of mucosa of various segments of alimentary tract in dog to acid-peptic action. Surgery 35:547-556, 1954.
25. Hirschowitz, B.I., Keeling, D., Lewin, M., Okabe, S., Parsons, M., Sewing, K., Wallmark, B., and Sachs, G. Pharmacological aspects of acid secretion. Dig. Dis. Sci. 40(suppl)3-23, 1995.
26. Orlando, R.C., and Bozymski, E.M. Heartburn in pernicious anemia: a consequence of bile reflux. N. Engl. J. Med. 283:522-523, 1973.
27. Gillen, P., Keeling, P., Byrne, P.J., Healy, M., O'Moore, R.R., Hennessy, T.P.J. Implication of duodenogastric reflux in the pathogenesis of Barrett's oesophagus. Br. J. Surg. 75:540-543, 1985.
28. Champion, G., Richter, J.E., Vaezi, M.F, Singh, S., and Alexander, R. Duodenogastroesophageal reflux: relationship to pH and importance in Barrett's esophagus. Gastroenterology 107:747-754, 1994.
29. Bortolotti, M., Abbati, A., Turba, E., Pozzato, R., Bersani, G., and Labo, G. 99mTc-HIDA dynamic scintigraphy for the diagnosis of gastroesophageal reflux of bile. Eur. J. Nucl. Med. 101:549-550, 1985.
30. Kauer, W.K.H., Burdiles, P., Ireland, A.P., Clark, G.W.B., Peters, J.H., Bremner, C.G., and DeMeester, T.R. Does duodenal juice reflux into the esophagus of patients with complicated GERD? Evaluation of a fiberoptic sensor for bilirubin. Am. J. Surg. 169:98-104, 1995.
31. Caldwell, M.T.P., Lawlor, P., Byrne, P.J., Walsh, T.N., and Hennessy, T.P.J. Ambulatory oesophageal bile reflux monitoring in Barrett's oesophagus. Br. J. Surg. 82:657-660, 1995.
32. Johnson, L.F. and DeMeester, T.R. Twenty-four-hour pH monitoring to the distal esophagus: a quantitative measure of gastroesophageal reflux. Am. J. Gastroenterol. 62:325-332, 1974.
33. Robertson, D., Aldersley, M., Shepherd, H., and Smith, C.L. Pattern of acid reflux in complicated oesophagitis. Gut 28:1484-1488, 1987.
34. De Caestecker, J.S., Blackwell, J.N., Pryde, A., and Heading, R.C. Daytime gastro-oesophageal reflux is important in oesophagitis. Gut 28:519-26, 1987.
35. Gudmundsson, K., Johnsson, F., and Joelsson, B. The time pattern of gastro-esophageal reflux. Scand. J. Gastroenterol. 23:75-9, 1988,
36. Kruse-Andersen, S., Wallin, L., and Madsen, T. Reflux patterns and related oesophageal motor activity in gastro-oesophageal reflux disease. Gut 31:633-8, 1990.
37. Boesby, S. Relationship between gastro-oesophageal acid reflux, basal gastro-oesophageal sphincter pressure, and gastric acid secretion. Scand. J. Gastroenterol. 12:547-51, 1977.
38. Madkainen, M. Gastric acid secretion, oesophageal acid reflux, and oesophagitis in patients with symptomatic gastro-oesophageal reflux. Scand. J. Gastroenterol. 16:1043-1048, 1981.
39. Johansson, K.E., Ask, P., Boeryd, B., Fransson, S.G., and Tibbling, L. Oesophagitis, signs of reflux, and gastric acid secretion in patients with symptoms of gastro-oesophageal reflux disease. Scand. J. Gastroenterol. 21:837-847, 1986.
40. Schindlbeck, N.E., Heinrich, C., Konig, A., Dendorfer, A., Pace, F., and Muller-Lissner, S.A. Optimal thresholds, sensitivity, and specificity of the long term pH-metry for the detection of gastroesophageal reflux disease. Gastroenterology 93:85-90, 1987.
41. Barrientos, M., Tougas, G., Armstrong, D., Sontag, S., and Hunt, R.H. A predictive model of mucosal damage in GERD using area under the curve estimation of hydrogen ion activity (AUC H+). Gastroenterology 108:A55, 1995.
42. Sontag, S.J. Rolling review: gastro-oesophageal reflux disease. Aliment. Pharmacol. Therap. 7:293-312, 1993.
43. Roufail, W., Belsito, A., Robinson, M., Barish, C., and Rubin, A. Ranitidine for erosive oesophagitis: a double-blind, placebo-controlled study. Glaxo Erosive Esophagitis Study Group. Aliment. Pharmacol. Therap. 6:597-607, 1992.
44. Euler, A.R., Murdock, R.H., Wilson, T.H., Silver, M.T., Parker, S.E., and Powers, L. Ranitidine is effective therapy for erosive esophagitis. Am. J. Gastroenterol. 88:520-524, 1993.
45. Boyd, E.J. and Wood, J.R. H2-receptor antagonist in the treatment of reflux oesophagitis. Scand. J. Gastroenterol. 24(suppl 171):136-143, 1989.
46. Hunt, R.H. The relationship between the control of pH and healing and symptom relief in gastro-oesophageal reflux disease. Aliment. Pharmacol. Therap. 9(suppl 1):3-7, 1995.
47. Bell, N.J.V. and Hunt, R.H. Role of gastric acid suppression in the treatment of gastrooesophageal reflux disease. Gut 33:118-124, 1992.
48. Chiba, N., de Gara, C.J., Burget, D.W., Wilkinson, J., and Hunt, R.H. Rapidity of healing in GERD: a comparison of different drug classes by meta-analysis. Gastroenterology 104:A53, 1993.
49. Chiba, N., Wilkinson, J., and Hunt, R.H. Symptom relief in erosive GERD: a meta-analysis. Am. J. Gastroenterol 88:1486, 1993. Abstract.
50. Bader, J.P. and Delchier, J.C. Clinical efficacy of pantoprazole compared with ranitidine. Aliment. Pharmacol. Therap. 8(suppl 1):47-52, 1994.
51. Mossner, J., Holscher, A.H., Herz, R., and Schneider, A. A double-blind atudy of pantoprazole and omeprazoleinthe treatment of reflux oesophagitis: a multicentre trial. Aliment. Pharmacol. Therap. 9:321-326, 1995.
52. Lundell, L., Backman, L., Ekstrom, P., Enander, L.K., Falkmer, S., Fausa, O., Grimelius, L., Havu, N., Lind, T., Lonroth, H., Sandmark, S., Sandzen, B., Unge, P., and Westin, I.H. Prevention of relapse of reflux esopahgitis after endoscopic healing: the efficacy and safety of omeprazole compared with ranitidine. Scand. J. Gastroenterol. 26:248-256, 1991.
53. Robinson, M., Campbell, D.R , Sontag, S., and Sabesin, S.M. Treatment of erosive reflux esophagitis resistant to H2-receptor antagonist therapy. Dig. Dis. Sci. 40:590-597, 1995.
54. Feldman, M., Harford, W.V., Fisher, R.S., Sampliner, R.E., and Murray, S.B. Treatment of reflux esophagitis resistant to H2-receptor antagonist with lansoprazole, a new H+/K+- ATPase inhibitor: a controlled, double-blind study. Lansoprazole Study Group. Am. J. Gastroenterol. 88:1212-1217, 1993.
55. Bardhan, K.D., Morris, P., Thompson, M., Dhande, D.S., Hinchliffe, R.F.C., Jones, R.B., Daly, M.J., and Carroll, N.J.H. Omeprazole in the treatment of erosive oesophagitis refractory to high dose cimetidine and ranitidine. Gut 31:745-774, 1990.
56. Lanzon-Miller, S., Pounder, R.E., Hamilton, M.R., Ball, S., Chronos, N.A.F., Raymond, F., Olausson, M., and Cederberg, C. Twenty-four-hour intragastric acidity and plasma gastrin concentration before and during treatment with either ranitidine or omeprazole. Aliment. Pharmacol. Therap. 1:239-251, 1987.
57. Pasqual, J.C., Hemery, P., Bruley, S., and Galmiche, J.P. Comparison of the effect of two doses of omeprazole on 24-hour esophageal pH in gastroesophageal reflux disease. Gastroenterology 92:1567, 1987. Abstract.
58. Tolman, K.G., Sanders, S.W., and Buchi, K.N. Gastric pH levels after 15 mg and 30 mg of lansoprazole and 20mg omeprazole. Gastroenterology 106:A197, 1994.
59. Londong, W. Effect of pantoprazole on 24-h intragastric pH and serum gastrin in humans. Aliment. Pharmacol. Therap. 8(suppl 1):39-46, 1994.
60. Feldman, M. and Richardson, C.T. Total 24-hour gastric acid secretion in patients with duodenal ulcer: comparison with normal subjects and effects of cimetidine and parietal cell vagotomy. Gastroenterology 90:540-544, 1986.
61. Merki, H.S., Fimmel, C.J., Walt, R.P., Harre, K., Rohmel, J., and Witzel, L. Pattern of 24 hour intragastric acidity in active duodenal ulcer disease and in healthy controls. Gut 29:1583-7, 1988.
62. Baron, J.H. The relationship between basal and maximal acid output in normal subjects and patients with duodenal ulcer. Clin. Sci. 24:357-70, 1963.
63. Pounder, R.E. and Fraser, A.G. Gastric acid secretion and intragastric acidity: measurement in health and disease. Baillieres Clin. Gastroenterol. 7:55-80, 1993.
64. Hunt, R.H., Cederberg, C., Dent, J., Halter, F., Howden, C.W., Solly-Marks, I.N., Rune, S., and Walt, R.P. Optimizing acid suppression for treatment of acid-related diseases. Dig. Dis. Sci. (suppl):40:24S-49S, 1995.
65. Smith, A.W.M. The pain of peptic ulceration, QJM 96:393-407, 1995.
66. McColl, K.E.L. and Fullarton, G.M. Duodenal ulcer pain: the role of acid and inflammation. Gut 34:1300-1302, 1993.
67. Kang, J.Y., Yap, I., Guan, R., and Tay, H.H. Acid perfusion of duodenal ulcer craters and ulcer pain: a controlled double blind study. Gut 27:942-945, 1986.
68. Kang, J.Y., Yap, I.V.Y., Guan, R., Tay, H.H., and Math, M.V. Acid induced duodenal ulcer pain: the influence of symptom status and the effect of an antispasmotic. Gut 30:166-70, 1989.
69. Bendtsen, F., Rosenkilde-Gram, B., Tag-Jensen, U., Ovesen, L., and Rune, S.J. Duodenal bulb acidity in patients with duodenal ulcer. Gastroenterology 93:1263-1269, 1987.
70. Kang, JY. Duodenal ulcer pain: the role of acid and inflammation (letter to the editor). Gut 35: 863-864, 1993.
71. McCloy, R. and Nair, R. Surgery for acid suppression in the 1990s. Bailliere Clin. Gastroenterol. 7:129-148, 1993.
72. Palmer, W.L. The therapy of peptic ulcer. II. Radiation therapy. In: Bockus, H.L., ed. Gastroenterology. Philadelphia: Saunders; 1974.
73. Schamburek, R.D. and Schubert, M.L. Pharmacology of gastric acid inhibition. Bailliere Clin. Gastroenterol. 7:23-54, 1993.
74. Dragstedt, L.R. Peptic ulcer: an abnormality in gastric secretion. Am. J. Surg. 117:143-156, 1969.
75. Gledhill, T., Howard, O.M., Buck, M., Paul, A., and Hunt, R.H. Single nocturnal dose of an H2 receptor antagonist for the treatment of duodenal ulcer. Gut 24:904-908, 1983.
76. Ireland, A., Colin-Jones, D.G., Gear, P., Golding, P.L., Ramage, J.K., Williams, J.G., Leicester R.J., Smith, C.L., Ross, G., Bamforth, J., DeGara, C.J., Gledhill, T., and Hunt, R.H. Ranitidine 150 mg twice daily vs. 300 mg nightly in the treatment of duodenal ulcers. Lancet ii:274-276, 1984.
77. Gitlin, N., McCullough, A.J., Smith, J.L., Mantell, G, and Berman, R. A multicenter, double-blind, randomized, placebo-controlled comparison of nocturnal and twice-a-day famotidine in the treatment of active duodenal ulcer disease. Gastroenterology 92:48-53, 1987.
78. Lee, F.I., Reed, P.I, Crowe, J.P., McIsaac, R.L., Wood, R.. Acute treatment of duodenal ulcer: a multicentre study to compare ranitiditine 150 mg twice daily with ranitidine 300 mg once at night. Gut 27:1091-1095, 1986.
79. Jones, D.B., Howden, C. W., Burget, D.W., Kerr, G.D., and Hunt, R.H. Acid suppression in duodenal ulcer: a meta-analysis to define optimal dosing with antisecretory drugs. Gut 28:1120-1127, 1987.
80. Lanzon-Miller, S., Pounder, R.E., Hamilton, M.R., Ball, S., Chronos, N.A.F., Raymond, F., Olausson, M., and Cederberg, C. Twenty-four-hour intragastric acidity and plasma gastrin concentration before and during treatment with either ranitidine or omeprazole. Aliment. Pharmacol. Therap. 1:239-251, 1987.
81. Hunt, R.H., Malfertheiner, P., Yeomans, N.D., Hawkey, C.J., and Howden, C.W. Critical issues in the pathophysiology and management of peptic ulcer disease. Europ. J. Gastroenterol. Hepatol. 7:685-699, 1995.
82. Eriksson, S., Langstrom, G., Rikner, L., Carlsson, R., and Naesdal, J. Omeprazole and H2-receptor antagonists in the acute treatment of duodenal ulcer, gastric ucler and reflux esopahgitis: a meta-analysis. Europ. J. Gastroenterol. Hepatol. 7:467-475, 1995.
83. Poynard, T., Lemaire, M., Agostini, H. Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer. Eur. J. Gastroenterol. Hepatol. 7:661-665, 1995.
84. Morgan, D.G., Burget, D.W., Howden, C.W., Jacobson, K., Wang, D., Hewak, J., Wilkinson. J., and Hunt, R.H. Rates of duodenal ulcer (DU) healing by drug classes: A meta-analysis. Gastroenterology 104:A150, 1993.
85. Morgan, D.G., Burget, D.W., Howden, C.W., Jacobson, K., Wang, D., Hewak, J., Wilkinson, J., and Hunt, R.H. Duodenal ulcer(DU) healing: little difference in healing rates within drug classes. Gastroenterology 106:A143, 1994.
86. Hawkey, C.J., Long, R.G., Bardhan, K.D., Wormsley, K.G., Cochran, K.M., Christian, J., and Moules, I.K. Improved symptom relief and duodenal ulcer healing with lansoprazole, a new proton pump inhibitor, compared with ranitidine. Gut 34:1458-1462, 1993.
87. Hotz, J., Kleinert, R., Grymbowski, T, Hennig, U., and Schwarz, J.A. Lansoprazole versus famotidine:efficacy and tolerance in the acute management of duodenal ulceration. Aliment. Pharmacol. Therap. 6:87-95, 1992.
88. Ekstrom, P., Carling, L., Unge, P., Anker-Hansen, O., Sjostedt, S., and Sellstrom, H. Lansoprazole versus omeprazole in active duodenal ulcer: a double-blind, randomized, comparative study. Scand. J. Gastroenterol. 30:210-215, 1995.
89. Beker, J.A., Bianchi-Porro, G., Bigard, M., Fave, G.D., Devis, G., Gouerou, H., and Maier, C. Double-blind comparison of pantoprazole and omeprazole for the treatment of acute duodenal ulcer. Europ. J. Gastroenterol. Hepatol. 7:407-410, 1995.
90. Schepp, W., Rehner, M., and Witzel, L. A review of treatment of duodenal and gastric ulcer: pantoprazole vs. omeprazole. Aliment. Pharmacol. Therap. 8(suppl 1):53-57, 1994.
91. Delhotal-Landes, B., Flouvat, B., Duchier, J., Molinie, P., Dellatolas, F., Lemaire, M. Pharmacokinetics of lansoprazole in patients with renal or liver disease of varing severity. Eur. J. Clin. Pharmacol. 45:367-371, 1993.
92. Hosking, S.W., Ling, T.K.W., Chung, S.C.S., Yung, M.Y., Cheng, A.F.B., Sung, J.J.Y., and Li A.K.C. Duodenal ulcer healing by eradication of Helicobacter pylori without anti-acid treatment: randomized controlled trial. Lancet 343:508-510, 1994.
93. Seppala, K., Farkkila, M., Nuutinen, H., Hakala, K., Vaananen, H., Rautelin, H., and Kosunen, T.U. Triple therapy of helicobacter pylori infection in peptic ulcer: a 12-month follow-up study of 93 patients. Scand. J. Gastroenterol. 27:973-976, 1992.
94. Bianchi-Porro, G., Parente, F., and Lazzaroni, M. Short and long-term outcome of Helicobacter pylori positive resistant duodenal ulcers treated with colloidal bismuth subcitrate plus antibiotics or sucralphate alone. Gut 34:466-469, 1993.
95. Graham, D.Y., Lew, G.M., Evans, D.G., Evans, D.J., and Klein, P.D. Effect of triple therapy (antibiotics plus bismuth) on duodenal ulcer healing: a randomized controlled trial. Ann. Intern. Med. 115:266-269, 1991.
96. Hunt, R.H., Schwartz, H., Fitch, D., Fedorak, R., Al Kawas, F., and Vakil, N. Clarithromycin Study Group: dual therapy of clarithromycin (CL) and omeprazole (OM) for treatment of patients with duodenal ulcers (DU) associated with H. pylori (HP) infection. Gut (suppl 1):17, 1995.
97. O'Morain, C., Logan, R.P.H., and the Clarithromycin European H. Pylori Study Group. Clarithromycin (CL) in combination with omeprazole (OM) for healing of duodenal ulcers (DU), prevention of DU ercurrence, and eradication of H. pylori (HP) in two European studies. Gut (suppl 1):16, 1995.
98. Labenz, J., Adamek, R.J., Idstrom, J.P., Peitz, U., Tillenburg, B., and Borsch, G. Duodenal ulcer healing and Helicobacter pylori eradication by one-week low-dose triple therapy with omeprazole, clarithromycin and metronidazole. Gut (suppl 1):164, 1995.
99. Axon, A.T.R. The role of acid inhibition in the treatment of helicobacter pylori infection. Scand. J. Gastroenterol. 29(suppl 201):16-23, 1994.
100. Prewett, E.J., Smith, J.T.L., Nwokolo, C.U., Hudson, M., Sawyerr, A.M., and Pounder, R.E. Eradication of helicobacter pylori abolishes 24-hour hypergastrinaemia: a prospective study in healthy subjects. Aliment. Pharmacol. Therap. 5:283-290, 1991.
101. El-Omar, E., Penman, I., Dorrian, C.A., Ardill, J.E.S., and McColl, K.E.L. Eradicating Helicobacter pylori infection lowers gastrin mediated acid secretion by two thirds in patients with duodenal ulcer. Gut 34:1060-1065, 1993.
102. Muller, M.J. and Hunt, R.H. Inflammation, acid and ulcers. Yale J. Biol. Med. 67:135-44, 1994.
103. Graham, D.Y., Lew, G.M., Malaty, H.M., Evans, D.G., Evans, D.J., Klein, P.D., Alpert, L.C., and Genta, R.M. Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology 102:493-496, 1992.
104. Battaglia, G., DiMario, F., Dotto, P., Leandro, G., Pilotto, A., Ferrana, M.. Vianello, F., Vignen, S., Colonna, C.V., and Naccarato, R. Markers of slow-healing peptic ulcer in the elderly A study on 1,052 ranitidine-treated patients. Dig. Dis. Sci. 38:1414-1421. 1993.
105. Armstrong, D., Arnold, R., Classen, M., Fischer, M., Goebell, H., and Blum, A.L., The RUDER Study Group. Prospective multicentre study of risk factos associated with delayed healing of recurrent duodenal ulcers (RUDER). Gut 34:1319-1326, 1993.
106. Sonnenberg, A., Muller-Lissner, A., Vogel, E., Schmid, P., Gonvers, J.J., Peter, P., Strohmeyer, G., and Blum, A.L. Predictors of duodenal ulcer healing and relapse. Gastroenterology 81:1061-1067, 1981.
107. Endoh, K. and Leung, F.W. Effects of smoking and nicotine on the gastric mucosa: a review of clinical and experimental evidence. Gastroenterology 107:864-878, 1994.
108. Derodra, J.K., Burget, D.W., and Hunt, R.H. Effects of oral nicotine on the formation of acetic acid induced gastric and duodenal ulcer. Gastroenterology 92:1369, 1987. Abstract.
109. Valenzuela, J.E., Berlin, R.G., Snape, W.J., Johnson, T.L, Hirschowitz, B.L., Colon-Pagan, J., Morse, R.S., Petrozza, J., Danventer, G.M., Cagliola, A., Whipple, J., Berman, R., and Humphries, T.J. U.S. experience with omeprazole in duodenal ulcer multicenter double-blind comparative study with ranitidine. The Omeprazole DU Comparative Study Group. Dig. Dis. Sci. 36:761-768, 1991.
110. Grossman, M.I., Kirsner, J.B., Gillespie, I.E. Basal and histalog-stimulated gastric secretion in control subjects and in patients with peptic ulcer or gastric cancer. Gastroenterology 45:14-26, 1963.
111. Kinsella, V.J. and Sydney, M.D. Pain in chronic gastric ulcer: basic anatomy and mechanism. Lancet i:353-361, 1953.
112. Howden, C.W., Jones, D.B., Peace, K.E., Burget, D.W., and Hunt, R.H. The treatment of gastric ulcer with antisecretory drugs: relationship of pharmacological effect to healing rates. Dig. Dis. Sci. 33:619-624, 1988.
113. Howden, C.W. and Hunt, R.H. The relationship between suppression of acidity and gastric ulcer healing rates. Aliment. Pharmacol. Therap. 4:25-33, 1990.
114. Walan, A., Bader, J., Classen, M., Lamers, C.B.H.W., Piper, D.W., Rutgersson, K., and Eriksson, S. Effect of omeprazole and ranitidine on ulcer healing and relapse rates in patients with benign gastric ulcer. N. Engl. J. Med. 320:69-75, 1989.
115. Bate, C.M., Wilkinson, S.P., Bradby, G.V.H., Bateson, M.C., Hislop, W.S., Crown, J.P., Willoughby, C.P., Peers, E.M., and Richardson, P.D.I. Randomized, double-blind comparison of omeprazole and cimetidine in the treatment of symptomatic gastric ulcer. Gut 30:1323-1328, 1989.
116. Michel, P., Lemaire, M., Colin, R., Bommelaer, G., Rambaud, J.C., Dupas, J.L., Bigard, M.A, and Verwaerd, J.C. Short report: treatment of gastric ulcer with lansoprazole or ranitidine: a multicentre clinical trial. Aliment. Pharmacol. Therap. 8:119-122, 1994.
117. Bardhan, K.D., Ahlberg, J., Hislop, W.S., Lindholmer, C., Long, R.G., Morgan, A.G., Sjostedt, S., Smith, P.M., Stig, R., Wormsley, K.G., Langworthy, H., and Moules, I.K. Rapid healing of gastric ulcer with lansoprazole. Aliment. Pharmacol. Therap. 8:215-220, 1994.
118. Hotz, J., Plein, K., Schonekas, H., and Rose, K. Pantoprazole is superior to rantidine in the treatment of acute gastric ucler. Scand. J. Gastroenterol. 30:111-115, 1995.
119. Florent, C., Audigier, J.C., Boyer, J., Camatte, R., Corallo, J., Delmont, J., Doffoel, M., Escourrou, J., Evreux, M., Gipoulou, V., Laugier, R., Paris, J.C., Pascal, J.P., Pienkowski, P., Rampal, P., and Joubert-Collin, M. Efficacy and safety of lansoprazole in the treatment of gastric ulcer: a multicentre study. Europ. J. Gastroenterol. Hepatol. 6:1135-1139, 1994.
120. Tatsuta, M., Iishi, H., and Yokota, Y. Effects of Helicobacter pylori on healing and recurrence of gastric ulcers. Am. J. Gastroenterol. 90:406-410, 1995.
121. Tatsuta, M., Ishikawa, H., Iishi, H., Okuda, S., and Yokota, Y. Reduction of gastric ulcer recurrence after suppression of Helicobacter pylori by cefixime. Gut 31:973-976, 1990.
122. Sung, J.J.Y., Chung, S.C.S., Ling, T.K.W, Yung, M.Y., Leung, V.K.S., Ng, E.K.W., Li, M.K.K., Cheng, A.F.B., and Li, A.K.G. Antibacterial treatment of gastric ulcers associated with Helicobacter pylori. N. Engl. J. Med. 332:139-142, 1995.
123. Huang, J., and Hunt, R.H. A clinician's view of strategies for preventing NSAID-induced gastrointestinal ulcers. Inflammopharmacol. 4:17-30, 1996.